-
公开(公告)号：US20220160632A1
公开(公告)日：2022-05-26
申请号：US17560594
申请日：2021-12-23
发明人： Christopher B. Fox , Susan S. Lin , Darrick Carter , Neal Van Hoeven , Mayuresh M. Abhyankar , William A. Petri
IPC分类号： A61K9/127 , A61K31/739 , A61K39/39
摘要： Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
-
公开(公告)号：US10765736B2
公开(公告)日：2020-09-08
申请号：US15823852
申请日：2017-11-28
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/395 , A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
3.发明申请公开(公告)号：US20200148729A1
公开(公告)日：2020-05-14
申请号：US16098911
申请日：2017-05-19
发明人： Rhea N. Coler
摘要： Provided herein are fusion polypeptides comprising at least two Mycobacterial antigens, wherein one Mycobacterial antigen is a strong central memory T cell activator, and wherein one Mycobacterial antigen is a strong effector memory T cell activator. Also provided herein are methods of making and using such fusion polypeptides for the prevention or treatment of a secondary Mycobacterium tuberculosis infection as well as for the prevention or treatment of a nontuberculous Mycobacterium infection in a mammal.
-
公开(公告)号：US20190328868A1
公开(公告)日：2019-10-31
申请号：US16473393
申请日：2017-12-20
发明人： Hyo Jung NAM , Eun Mi KIM , Duck Hyang SHIN , Steven G. REED , Kang Il YOO , Sung Jun HONG
IPC分类号： A61K39/25 , A61K39/39 , A61P31/22 , G01N33/569
摘要： The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
-
公开(公告)号：US20180221470A1
公开(公告)日：2018-08-09
申请号：US15823852
申请日：2017-11-28
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/39 , A61K9/107 , A61K39/00 , A61K39/145 , A61K39/04 , A61K39/008 , A61K45/06 , A61K39/35
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
公开(公告)号：US09480740B2
公开(公告)日：2016-11-01
申请号：US14222481
申请日：2014-03-21
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/39 , A61K39/00 , A61K39/04 , C07H15/12 , A61K39/21 , A61K39/235 , A61K39/245 , A61K39/275 , C07H15/20
CPC分类号： A61K39/39 , A61K9/107 , A61K31/665 , A61K31/7016 , A61K39/00 , A61K39/04 , A61K39/21 , A61K39/235 , A61K39/245 , A61K39/275 , A61K2039/525 , A61K2039/55572 , A61K2039/57 , A61K2039/575 , C07H15/04 , C07H15/12 , C07H15/20
摘要： Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
-
公开(公告)号：US09463198B2
公开(公告)日：2016-10-11
申请号：US14256881
申请日：2014-04-18
IPC分类号： A01N43/04 , A61K31/715 , A61K31/7024 , A61K31/7008 , A61K31/7016 , A61K31/7012 , A61K31/138 , A61K31/407 , A61K45/06
CPC分类号： A61K31/7024 , A61K31/138 , A61K31/407 , A61K31/7008 , A61K31/7012 , A61K31/7016 , A61K45/06
摘要： Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.
摘要翻译： 提供了包含吡喃葡萄糖基脂质佐剂（GLA）的组合物和利用其减少或预防癌症转移形成的方法。 组合物可以配制用于局部 - 区域递送。 组合物可以基本上没有癌抗原。 用GLA治疗可以与COX2抑制剂和β-肾上腺素能阻滞剂联合治疗。
-
公开(公告)号：US09408899B2
公开(公告)日：2016-08-09
申请号：US13823668
申请日：2011-11-03
申请人： Rima McLeod , Tze Guan Tan , Jeffery L. Alexander , Hua Cong , William H. Witola , Kamal El Bissati , Ernest J. Mui , Steven G. Reed
发明人： Rima McLeod , Tze Guan Tan , Jeffery L. Alexander , Hua Cong , William H. Witola , Kamal El Bissati , Ernest J. Mui , Steven G. Reed
IPC分类号： A61K39/00 , A61K39/39 , A61K39/002
CPC分类号： A61K39/002 , A61K2039/55572 , A61K2039/6031
摘要： Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is Toxoplas gondii.
摘要翻译： 针对寄生虫披露疫苗。 疫苗包括免疫组成中的肽。 特别地，寄生虫是弓形虫（Toxoplas gondii）。
-
9.发明申请VACCINES COMPRISING LEISHMANIA POLYPEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS 有权包含LEISHMANIA POLYPEPTIES用于治疗和诊断淋巴瘤的疫苗公开(公告)号：US20160186158A1
公开(公告)日：2016-06-30
申请号：US14780504
申请日：2014-03-28
发明人： Malcolm DUTHIE , Jeff GUDERIAN , Steven G. REED
IPC分类号： C12N9/24 , G01N33/569 , C12N9/10 , A61K39/008
CPC分类号： C12N9/2497 , A61K39/008 , C12N9/1007 , C12Y201/01041 , C12Y302/02001 , G01N33/56905 , G01N2333/44 , G01N2469/20 , Y02A50/41
摘要： Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising Leishmania antigens as well as polynucleotides encoding such polypeptides.
摘要翻译： 公开了用于预防，治疗和检测利什曼病的组合物和方法。 组合物通常包含包含利什曼原虫抗原的多肽以及编码这种多肽的多核苷酸。
-
公开(公告)号：US20150087615A1
公开(公告)日：2015-03-26
申请号：US14256881
申请日：2014-04-18
IPC分类号： A61K31/7024 , A61K31/138 , A61K31/407 , A61K45/06
CPC分类号： A61K31/7024 , A61K31/138 , A61K31/407 , A61K31/7008 , A61K31/7012 , A61K31/7016 , A61K45/06
摘要： Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.
摘要翻译： 提供了包含吡喃葡萄糖基脂质佐剂（GLA）的组合物和利用其减少或预防癌症转移形成的方法。 组合物可以配制用于局部 - 区域递送。 组合物可以基本上没有癌抗原。 用GLA治疗可以与COX2抑制剂和β-肾上腺素能阻滞剂联合治疗。
-
-
-
-
-
-
-
-
-
搜索结果
87 条记录 (耗时 0.042 秒)
